公开(公告)号：US20220332767A1

公开(公告)日：2022-10-20

申请号：US17848247

申请日：2022-06-23

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Kurt SWANSON ,  Andrea CARFI

IPC: C07K14/005 ,  A61K39/12 ,  A61K39/155

Abstract: The invention relates to pre-fusion RSV F protein and polypeptides that contain one or more amino acid mutations that stabilize the pre-fusion conformation or destabilize the post-fusion conformation. The invention also relates to methods for inducing an immune response to pre-fusion RSV F.

公开(公告)号：US20220332766A1

公开(公告)日：2022-10-20

申请号：US17848230

申请日：2022-06-23

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Kurt SWANSON ,  Andrea CARFI

IPC: C07K14/005 ,  A61K39/12 ,  A61K39/155

Abstract: The invention relates to pre-fusion RSV F protein and polypeptides that contain one or more amino acid mutations that stabilize the pre-fusion conformation or destabilize the post-fusion conformation. The invention also relates to methods for inducing an immune response to pre-fusion RSV F.

公开(公告)号：US20240239845A1

公开(公告)日：2024-07-18

申请号：US18596426

申请日：2024-03-05

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Kurt SWANSON ,  Andrea CARFI

IPC: C07K14/005 ,  A61K39/00 ,  A61K39/12 ,  A61K39/155

CPC classification number: C07K14/005 ,  A61K39/12 ,  A61K39/155 ,  A61K2039/53 ,  C07K2319/735 ,  C12N2760/18522 ,  C12N2760/18534

Abstract: The invention relates to pre-fusion RSV F protein and polypeptides that contain one or more amino acid mutations that stabilize the pre-fusion conformation or destabilize the post-fusion conformation. The invention also relates to methods for inducing an immune response to pre-fusion RSV F.

公开(公告)号：US20210269489A1

公开(公告)日：2021-09-02

申请号：US17314649

申请日：2021-05-07

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Kurt SWANSON ,  Andrea CARFI

IPC: C07K14/005 ,  A61K39/12 ,  A61K39/155

Abstract: The invention relates to pre-fusion RSV F protein and polypeptides that contain one or more amino acid mutations that stabilize the pre-fusion conformation or destabilize the post-fusion conformation. The invention also relates to methods for inducing an immune response to pre-fusion RSV F.

公开(公告)号：US20180237476A1

公开(公告)日：2018-08-23

申请号：US15789074

申请日：2017-10-20

Applicant: GLAXOSMITHKLINE BIOLOGICALS, SA

Inventor： Kurt SWANSON ,  Andrea CARFI

IPC: C07K14/005 ,  A61K39/12 ,  A61K39/155

CPC classification number: C07K14/005 ,  A61K39/12 ,  A61K39/155 ,  A61K2039/53 ,  C07K2319/735 ,  C12N2760/18522 ,  C12N2760/18534

Abstract: The invention relates to pre-fusion RSV F protein and polypeptides that contain one or more amino acid mutations that stabilize the pre-fusion conformation or destabilize the post-fusion conformation. The invention also relates to methods for inducing an immune response to pre-fusion RSV F.

公开(公告)号：US20210277067A1

公开(公告)日：2021-09-09

申请号：US17223207

申请日：2021-04-06

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Enrico MALITO ,  Matthew James BOTTOMLEY ,  Andrea CARFI ,  Sumana CHANDRAMOULI ,  Kate LUISI

IPC: C07K14/045 ,  A61K39/245 ,  A61K38/00

Abstract: Described are mutant human cytomegalovirus (HCMV) pentamer complex polypeptides, methods of making them, and their use in HCMV protein complexes and compositions. In particular, the use of the modified HCMV polypeptides to stabilize HCMV complexes or unmask a pentamer epitope is described.

公开(公告)号：US20170369532A1

公开(公告)日：2017-12-28

申请号：US15544730

申请日：2016-01-22

Applicant: GLAXOSMITHKLINE BIOLOGICALS, SA

Inventor： Andrea CARFI ,  Claudio CIFERRI ,  Yi XING

IPC: C07K14/005 ,  A61K39/00

CPC classification number: C07K14/005 ,  A61K38/00 ,  A61K39/00 ,  A61K39/12 ,  A61K39/245 ,  A61K39/25 ,  A61K39/42 ,  A61K2039/525 ,  A61K2039/55566 ,  C07K16/081 ,  C07K16/082 ,  C12N7/00 ,  C12N2710/16122 ,  C12N2710/16134 ,  C12N2710/16151 ,  C12N15/86 ,  C12N2710/16143 ,  C07K2319/50 ,  C07K16/088 ,  C12N2810/6009 ,  C12N2710/16161

Abstract: This disclosure provides modified cytomegalovirus (CMV) gL proteins and complexes comprising gL proteins. The modified gL proteins remain intact and are able to form complexes with other CMV proteins.

公开(公告)号：US20230287056A1

公开(公告)日：2023-09-14

申请号：US18308583

申请日：2023-04-27

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Kurt SWANSON ,  Andrea CARFI

IPC: C07K14/005 ,  A61K39/12 ,  A61K39/155

CPC classification number: C07K14/005 ,  A61K39/12 ,  A61K39/155 ,  A61K2039/53

Abstract: The invention relates to pre-fusion RSV F protein and polypeptides that contain one or more amino acid mutations that stabilize the pre-fusion conformation or destabilize the post-fusion conformation. The invention also relates to methods for inducing an immune response to pre-fusion RSV F.

公开(公告)号：US20220106364A1

公开(公告)日：2022-04-07

申请号：US17551867

申请日：2021-12-15

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Andrea CARFI ,  Yingxia WEN

IPC: C07K14/005 ,  A61K39/12 ,  A61K39/245 ,  C12N7/00 ,  A61K39/00

Abstract: An isolated human cytomegalovirus (HCMV) membrane protein complex that comprises gH, gL and at least one more HCMV glycoprotein is provided. In some embodiments the complex consists of gH, gL and gO. In other embodiments the complex consists of gH, gL, pUL128, pUL130 and pUL131A. Processes for expressing and purifying such complexes, and subsequent uses of such complexes in immunogenic compositions and vaccines, are also provided.

公开(公告)号：US20250042951A1

公开(公告)日：2025-02-06

申请号：US18895059

申请日：2024-09-24

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Kurt SWANSON ,  Andrea CARFI

IPC: C07K14/005 ,  A61K39/00 ,  A61K39/12 ,  A61K39/155

Abstract: The invention relates to pre-fusion RSV F protein and polypeptides that contain one or more amino acid mutations that stabilize the pre-fusion conformation or destabilize the post-fusion conformation. The invention also relates to methods for inducing an immune response to pre-fusion RSV F.